Nanobiotix announces the publication of a peer-reviewed clinical case by researchers at the University of Texas MD Anderson Cancer Center in Clinical and Translational Radiation Oncology. The case study reports on a patient’s first experience receiving treatment with the potentially first-in-class radioenhancer, NBTXR3, for pancreatic duct adenocarcinoma.
As NBTXR3 could be a potential therapy for the treatment of all solid tumors alone or in combination with various anti-cancer agents, Nanobiotix and MD Anderson are collaborating to extend the development of NBTXR3 beyond the Company’s priority therapeutic areas (squamous cell carcinoma of locally advanced head and neck and immunotherapy). This ongoing Phase I study in pancreatic cancer is one of five ongoing Phase I or Phase II studies currently being conducted under this collaboration.
This phase I clinical trial evaluates the safety profile of NBTXR3 activated by radiotherapy in patients with locally advanced or borderline resectable PDAC, as well as the recommended dose for phase II (RP2D) for a future evaluation of the ‘efficiency. The case study, published in Clinical and Translational Radiation Oncology, focuses on the first patient to receive local endoscopic delivery of NBTXR3 into a deep visceral tumor. The patient is a 66-year-old man with locally advanced, unresectable PDAC who received local endoscopic NBTXR3 administration followed by intensity-modulated RT. CT imaging showed no visible leakage of the radioenhancer outside of the injected tumor. During the initial follow-up evaluation, the lesion remained radiographically stable, the patient did not present any toxicity related to the treatment suggesting the feasibility of the implementation of this treatment.
–
